These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23999876)

  • 21. A novel algorithm to improve specificity in ovarian cancer detection.
    Arjomandi A; Delanoy ML; Walker RP; Binder SR
    Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.
    Pedersen JW; Gentry-Maharaj A; Nøstdal A; Fourkala EO; Dawnay A; Burnell M; Zaikin A; Burchell J; Papadimitriou JT; Clausen H; Jacobs I; Menon U; Wandall HH
    Int J Cancer; 2014 May; 134(9):2180-88. PubMed ID: 24122770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.
    Zhang Z; Bast RC; Yu Y; Li J; Sokoll LJ; Rai AJ; Rosenzweig JM; Cameron B; Wang YY; Meng XY; Berchuck A; Van Haaften-Day C; Hacker NF; de Bruijn HW; van der Zee AG; Jacobs IJ; Fung ET; Chan DW
    Cancer Res; 2004 Aug; 64(16):5882-90. PubMed ID: 15313933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
    Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
    Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma.
    Xu YW; Chen H; Guo HP; Yang SH; Luo YH; Liu CT; Huang XY; Tang XM; Hong CQ; Li EM; Xu LY; Peng YH
    Gastric Cancer; 2019 May; 22(3):546-557. PubMed ID: 30426295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer.
    Tang L; Yang J; Ng SK; Rodriguez N; Choi PW; Vitonis A; Wang K; McLachlan GJ; Caiazzo RJ; Liu BC; Welch WR; Cramer DW; Berkowitz RS; Ng SW
    Eur J Cancer; 2010 Jan; 46(1):170-9. PubMed ID: 19926475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
    Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
    Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.
    McIntosh MW; Liu Y; Drescher C; Urban N; Diamandis EP
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4422-8. PubMed ID: 17671125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of candidate serologic markers for type I and type II ovarian cancer.
    Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
    Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
    Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
    Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.
    Gorelik E; Landsittel DP; Marrangoni AM; Modugno F; Velikokhatnaya L; Winans MT; Bigbee WL; Herberman RB; Lokshin AE
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):981-7. PubMed ID: 15824174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.
    Chang HW; Lee SM; Goodman SN; Singer G; Cho SK; Sokoll LJ; Montz FJ; Roden R; Zhang Z; Chan DW; Kurman RJ; Shih IeM
    J Natl Cancer Inst; 2002 Nov; 94(22):1697-703. PubMed ID: 12441325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
    Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
    J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
    Dewan R; Dewan A; Jindal M; Bhardawaj M
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
    Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
    Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125.
    Zheng X; Chen S; Li L; Liu X; Liu X; Dai S; Zhang P; Lu H; Lin Z; Yu Y; Li G
    J Gynecol Obstet Hum Reprod; 2018 Jun; 47(6):227-230. PubMed ID: 29609043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.
    Young Han C; Bedia JS; Yang WL; Hawley SJ; Bergan L; Hopper M; Celestino J; Guo J; Gornet TG; Soosaipillai A; Yang H; Doskocil SD; Lokshin AE; Handy BC; Diamandis EP; Moore RG; Lu KH; Lu Z; Anderson KS; Drescher CW; Skates SJ; Bast RC
    Br J Cancer; 2024 Mar; 130(5):861-868. PubMed ID: 38195887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomic approaches to tumor marker discovery.
    Rai AJ; Zhang Z; Rosenzweig J; Shih IeM; Pham T; Fung ET; Sokoll LJ; Chan DW
    Arch Pathol Lab Med; 2002 Dec; 126(12):1518-26. PubMed ID: 12456215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum-autoantibodies for discovery of prostate cancer specific biomarkers.
    Massoner P; Lueking A; Goehler H; Höpfner A; Kowald A; Kugler KG; Amersdorfer P; Horninger W; Bartsch G; Schulz-Knappe P; Klocker H
    Prostate; 2012 Mar; 72(4):427-36. PubMed ID: 22012634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.